Literature DB >> 1653574

A study on changes of coagulation inhibitors and fibrinolysis inhibitors in patients with liver cirrhosis and hepatoma.

C J Park1, H I Cho, S I Kim.   

Abstract

The authors conducted an investigation focusing mainly on the activities of the inhibitory factors of the coagulation and fibrinolysis processes in 35 normal adults and 72 liver cirrhosis and/or hepatoma patients. The activities of antithrombin III, protein C, and alpha 2-plasmin inhibitor were reduced to less than 50% in patients with decreased hepatic synthetic function while lupus anticoagulant was detected in more than 50% of patients with decreased hepatic synthetic function. Hemostatic abnormalities in advanced lived diseases may be caused partly by a decrease of coagulation and fibrinolysis inhibitors and the presence of lupus anticoagulant.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1653574      PMCID: PMC3049674          DOI: 10.3346/jkms.1991.6.1.1

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


  4 in total

Review 1.  Malignancies and catastrophic anti-phospholipid syndrome.

Authors:  Wolfgang Miesbach
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

Review 2.  Antiphospholipid syndrome and cancer.

Authors:  Eyal Reinstein; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

3.  Impact of sustained virus elimination on natural anticoagulant activity in patients with chronic viral hepatitis C.

Authors:  Aida Saray; Rusmir Mesihović; Zora Vukobrat-Bijedić; Srđan Gornjaković; Nenad Vanis; Amila Mehmedović; Vedad Papović; Sanjin Glavaš
Journal:  Bosn J Basic Med Sci       Date:  2013-05       Impact factor: 3.363

4.  Perioperative Thromboelastometry for Adult Living Donor Liver Transplant Recipients with a Tendency to Hypercoagulability: A Prospective Observational Cohort Study.

Authors:  Yasmin Kamel; Ashraf Hassanin; Abdel Rahman Ahmed; Emad Gad; Mohamed Afifi; Magdy Khalil; Klaus Görlinger; Khaled Yassen
Journal:  Transfus Med Hemother       Date:  2018-08-24       Impact factor: 3.747

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.